Almirall SA · BME:ALM

Almirall SA — Non-Deal Roadshow (May 2012)

30 slides from Almirall SA's roadshow presentation, May 2012

  1. Slide 1: Corporate Presentation

    Corporate Presentation May 2012

  2. Slide 2: Disclaimer

    Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptio

  3. Slide 3: Almirall at a glance

    Almirall at a glance 3 3

  4. Slide 4: Almirall in short

    Almirall in short  Revenues in 2011: € 873MM. European pharma  50% of International Sales. with global reach  Market Cap: € 1b.  Two major filings in 2011 (aclidinium, linaclotide). Recent launches,  R&D percentage on sales: 19%. significant pipeline  Six new products launched in last 18 month

  5. Slide 5: Almirall's business model

    Almirall’s business model In-house R&D • Focused strategy Branded, 12 affiliates in EU and LatAm • Nearly 20% over sales • Proprietary compounds well diversified portfolio Business marketed Development through… • Global reach • Strong track record • Recognized partnerships Partners in more than 70 c

  6. Slide 6: Growing internationally

    Growing internationally 2002 2007 2011 e2014 Affiliates 5 7 12 >15 % Intl. Sales 22% 34% 50% > 70% 6

  7. Slide 7: Strong track record in corporate development

    Strong track record in corporate development 2007 2008 2009 2010 2011 2012 Hermal GmbH Shire’s Portfolio (8 products) Tesavel® Toctino® Libertek® Xarelto® Linaclotide (sitagliptin) (alitretinoin) (roflumilast) (rivaroxaban) Europe Spain 10 countries Spain Spain Astucor® Conbriza® Silodyx® Cipralex®

  8. Slide 8: Strategic priorities looking forward

    Strategic priorities looking forward Effectively Manage the P&L Prepare the prepare, launch transition organization for and grow our new the future growth products 8

  9. Slide 9: Guidance 2012-14

    Guidance 2012-14 Barring unforeseen circumstances 2012 2013 2014 Sales Similar trends Revenues to accelerate sharply (€ MM) to 2011 Normalized Lower decline Lag effect on Net Income Profit growth than in 2011 profitability (€ MM) 9

  10. Slide 10: A new growth cycle unfolding

    A new growth cycle unfolding Transition of Almirall’s portfolio, barring unforeseen circumstances Sales CAGR: c. ‐8% Sales CAGR: double digit % 2009 2010 2011 2012 2013 2014 (Proportions are only indicative) 10

  11. Slide 11: Almirall's growth platforms

    Almirall’s growth platforms 11 11 11

  12. Slide 12: Two key growth platforms

    Two key growth platforms Aclidinium Linaclotide • Monotherapy submitted in • Submitted for approval in 2011 for approval in US and 2011 for IBS-C in Europe. EU. • First-in-class treatment with • Well positioned to be the unique efficacy and safety 2nd LAMA in the COPD profile. market. • No IBS-C pro

  13. Slide 13: Aclidinium

    Aclidinium Partnered in geograhies that represent >80% of worldwide sales. US Europe* Japan&Korea * Certain countries • Solid and direct presence in primary care and key geographies. • Non competing assets in development. • Excellent trade record in partnering. 13

  14. Slide 14: Aclidinium differentiation vs existing therapies

    Aclidinium differentiation vs existing therapies • Maximum efficacy from the 1st day of treatment and sustained over time. • Round-the-clock symptom control; early morning, day and night. • Superior bronchodilation during nighttime compared to tiotropium. • Clinically relevant improvements in qualit

  15. Slide 15: Genuair: superior inhalation device

    Genuair®: superior inhalation device Almirall’s design to address patients’ unmet needs What makes our inhaler different?  A ready-to-use (pre-loaded) multi-dose device.  Simple 2-step inhalation process: press and inhale.  Multiple feedback of correct inhalation: coloured window and click.  Pre

  16. Slide 16: Linaclotide

    Linaclotide Compound profile • Novel first-in-class compound for the treatment of IBS-C. • Once-a-day oral capsule. • Acts locally in the GI tract and is minimally absorbed. • Clinical studies involving nearly 1,600 patients with IBS-C have demonstrated sustained efficacy and a clean safety profile.

  17. Slide 17: Additional growth platforms

    Additional growth platforms Sativex® Derma franchise • Launched by Almirall in • Leading Derma player in three European countries in Europe. 2011. • Franchise that represents • Four additional launches 15% of total sales. planned in 2012. • Late stage derma pipeline • Phase III ongoing in progressin

  18. Slide 18: Sativex

    Sativex® Product fast facts • Sativex® is a first-in-class option indicated to treat high need patients with multiple sclerosis spasticity (MSS), who have failed to gain benefit from currently available treatments. • Nearly 700,000 people in Europe have MS, of which, up to 80% present spasticity (mu

  19. Slide 19: Evolution of latest launches and derma franchise

    Evolution of latest launches and derma franchise 32,5 15,5 29,4 9,9 + 56% + 10% € rounded Million *Actikerall, Efficib, Sativex, Silodyx, Tesavel and Toctino 19

  20. Slide 20: A pipeline with significant upside

    A pipeline with significant upside Preclinical and phase I projects not included Phase II Phase III Registration application Abediterol LAS40464 Aclidinium Aclidinium + OD LABA + ICS Formoterol Bromide Asthma/COPD COPD COPD LAS41004 Sativex® Linaclotide CB agonist Psoriasis IBS-C Oncological Pain LA

  21. Slide 21: What's next

    What´s next • Roll out of Sativex®. • Aclidinium PDUFA day in July. • Regulatory feedback for aclidinium and linaclotide in EU. • New licenses in line with our geographic and therapeutic priorities. • Partnering aclidinium in other geographies. 21

  22. Slide 22: Latest Results

    Latest Results 22 22 22

  23. Slide 23: Highlights YTD

    Highlights YTD Results YTD in line with guidance • Regulatory process on track for aclidinium and linaclotide. • Positive PADAC voting on aclidinium. • Aclidinium partnered in EU & Korea. • Positive 2nd MRP wave of Sativex® in EU. • Xarelto® co-promotion in Spain. • Solid Q1 results, guidande reiter

  24. Slide 24: Highlights Q1 2012

    Highlights Q1 2012 Solid Q1, 2012 guidance confirmed • Sales ahead of guidance (-5,9%). • International sales represent 57% (vs 44% in Q1 2011). • Solid balance sheet (Equity = 60,5%). • Positive Net Cash position. • Continued solid free cash flow generation. • Scrip dividend of € 0,18* per share ap

  25. Slide 25: Income Statement

    Income Statement YTD YTD € rounded Million % var Mar 2012 Mar 2011 Net Sales 200,2 212,7 (5,9%) Gross Profit 124,0 132,9 (6,7%) % of sales 61,9% 62,5% Other Income 20,7 23,7 (12,7%) • Sales ahead of R&D (38,0) (34,8) 9,2% guidance % of sales (19,0%) (16,4%) SG&A (91,8) (84,1) 9,2% % of sales (45,9%)

  26. Slide 26: Balance Sheet

    Balance Sheet March % December € rounded Million 2012 of BS 2011 Goodwill 270,9 18,8% 271,1 Intangible assets 344,4 23,8% 353,1 Property, plant and equipment 149,1 10,3% 152,1 Financial assets 8,8 0,6% 8,5 Other non current assets 229,0 15,8% 213,1 Total Non Current Assets 1.002,2 69,4% 997,9 Invent

  27. Slide 27: Cash Flow

    Cash Flow YTD YTD € rounded Million Mar 2012 Mar 2011 Profit Before Tax 13,1 34,3 Depreciation and amortisation 16,4 15,4 Change in working capital (29,5) (21,3) Other adjustments 30,4 3,1 Cash Flow from Operating Activities (I) 30,4 31,5 Financial Income 1,3 1,8 Investments (4,6) (5,7) Improved Fre

  28. Slide 28: Breakdown of the core business

    Breakdown of the core business Proprietary products In-licensing products YTD YTD € rounded million % Var YTD Mar 2012 Mar 2011 Ebastel and others (ebastine) 26,8 30,8 (13,1%) Almogran and others (almotriptan) 21,0 16,3 28,9% Plusvent (salmeterol & fluticasone) 14,8 15,4 (4,3%) Parapres (candesartan

  29. Slide 29: For further information, please contact

    For further information, please contact: Jordi Molina Investor Relations & Corporate Communication Ph. +34 93 291 3087 jordi.molina@almirall.com Or visit our website: www.almirall.com 29 29 29

  30. Slide 30: Almirall - Solutions with you in mind

    6 . (4 Almirall Solutions with you in mind

Almirall — Non-Deal Roadshow (May 2012) on 6ix